GoodRx Holdings, Inc. (GDRX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GDRX SEC filings page.
GoodRx Holdings, Inc. (GDRX) reported $785.2M in revenue over the twelve months to Jun 30, 2026, down 1.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is nearly flat, but lower overhead and continued cash generation have turned a thin-margin platform into a more profitable operation.
Revenue barely moved between FY2024 and FY2025, while operating margin expanded from8.3% to11.0% . With both SG&A and R&D lower, the pattern points to the cost base—not volume growth—as the main recent profit mechanism.
In FY2025, operating cash flow was
By FY2025, the current ratio was 2.6x and debt-to-equity was 0.8x, indicating a thinner liquidity cushion even as long-term debt remained below its FY2024 level. The shift coincided with equity falling to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of GoodRx Holdings, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
GoodRx Holdings, Inc. has an operating margin of 11.0%, meaning the company retains $11 of operating profit per $100 of revenue. This results in a moderate score of 48/100, indicating healthy but not exceptional operating efficiency. This is up from 8.3% the prior year.
GoodRx Holdings, Inc.'s revenue grew a modest 0.6% year-over-year to $796.9M. This slow but positive growth earns a score of 42/100.
GoodRx Holdings, Inc. has a moderate D/E ratio of 0.78. This balance of debt and equity financing earns a leverage score of 42/100.
With a current ratio of 2.61, GoodRx Holdings, Inc. holds $2.61 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 73/100.
GoodRx Holdings, Inc. converts 20.6% of revenue into free cash flow ($164.4M). This strong cash generation earns a score of 87/100.
GoodRx Holdings, Inc.'s ROE of 4.9% shows moderate profitability relative to equity, earning a score of 41/100. This is up from 2.3% the prior year.
GoodRx Holdings, Inc. scores 0.62, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.2B) relative to total liabilities ($787.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
GoodRx Holdings, Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, GoodRx Holdings, Inc. generates $5.52 in operating cash flow ($167.9M OCF vs $30.4M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
GoodRx Holdings, Inc. earns $2.05 in operating income for every $1 of interest expense ($87.5M vs $42.6M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
GoodRx Holdings, Inc. generated $200.4M in revenue in Q2 2026. This represents a decrease of 1.3% from the same quarter a year earlier. Against the prior quarter it is up 3.3%.
GoodRx Holdings, Inc.'s EBITDA was $45.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 1.4% from the same quarter a year earlier. Against the prior quarter it is up 28.2%.
GoodRx Holdings, Inc. reported $8.5M in net income in Q2 2026. This represents a decrease of 33.5% from the same quarter a year earlier. Against the prior quarter it is up 630.2%.
GoodRx Holdings, Inc. earned $0.02 per diluted share (EPS) in Q2 2026. This represents a decrease of 50.0% from the same quarter a year earlier.
Cash & Balance Sheet
GoodRx Holdings, Inc. generated $80.5M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 63.6% from the same quarter a year earlier. Against the prior quarter it is up 651.9%.
GoodRx Holdings, Inc. held $296.1M in cash against $481.6M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
GoodRx Holdings, Inc.'s gross margin was 89.5% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 3.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.1 percentage points.
GoodRx Holdings, Inc.'s operating margin was 11.8% in Q2 2026, reflecting core business profitability. This is down 1.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.6 percentage points.
GoodRx Holdings, Inc.'s net profit margin was 4.3% in Q2 2026, showing the share of revenue converted to profit. This is down 2.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.7 percentage points.
GoodRx Holdings, Inc.'s ROE was 1.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.
Capital Allocation
GoodRx Holdings, Inc. invested $26.7M in research and development in Q2 2026. This represents a decrease of 10.8% from the same quarter a year earlier. Against the prior quarter it is down 11.5%.
GoodRx Holdings, Inc. spent $2.0M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 95.8% from the same quarter a year earlier. Against the prior quarter it is down 84.5%.
GoodRx Holdings, Inc. invested $362K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 7.2% from the same quarter a year earlier. Against the prior quarter it is down 68.1%.
GDRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $200.4M-1.3% | $194.0M-4.4% | $194.8M-1.9% | $196.0M+0.4% | $203.1M+1.2% | $203.0M+2.6% | $198.6M+1.0% | $195.3M+8.5% |
| Cost of Revenue | $21.0M+57.3% | $20.2M+50.8% | $17.5M+43.2% | $13.4M+14.8% | $13.3M+12.5% | $13.4M+7.2% | $12.2M-19.6% | $11.7M-37.6% |
| Gross Profit | $179.4M-5.4% | $173.8M-8.3% | $177.3M-4.9% | $182.6M-0.5% | $189.7M+0.5% | $189.6M+2.3% | $186.4M+2.7% | $183.6M+13.8% |
| R&D Expenses | $26.7M-10.8% | $30.2M-3.1% | $28.9M-8.8% | $31.0M+2.9% | $29.9M-3.0% | $31.1M+0.4% | $31.7M-0.9% | $30.1M-23.9% |
| SG&A Expenses | $24.8M-12.6% | $26.8M-9.5% | $23.9M+1.7% | $32.0M+25.0% | $28.4M+2.9% | $29.6M-27.9% | $23.5M-22.5% | $25.6M-27.5% |
| Operating Income | $23.6M-11.9% | $14.0M-40.1% | $22.7M+24.8% | $14.6M-28.4% | $26.8M+34.9% | $23.4M+216.8% | $18.2M+199.4% | $20.4M+153.2% |
| EBITDA | $45.9M-1.4% | $35.8M-19.2% | $45.8M+22.9% | $36.1M-5.0% | $46.5M+26.3% | $44.3M+89.9% | $37.3M+47.2% | $37.9M+815.1% |
| Interest Expense | $9.8M-8.6% | $9.8M-8.2% | $10.4M-8.4% | $10.8M-12.4% | $10.7M-26.3% | $10.6M-27.3% | $11.4M-23.4% | $12.4M-16.1% |
| Income Tax | $6.9M+2.9% | $4.5M-20.4% | $8.8M+87.8% | $5.0M+20.1% | $6.7M+36.0% | $5.6M+331.3% | $4.7M+278.4% | $4.1M+151.2% |
| Net Income | $8.5M-33.5% | $1.2M-89.4% | $5.4M-20.2% | $1.1M-71.8% | $12.8M+91.9% | $11.1M+1195.3% | $6.8M+126.1% | $4.0M+110.3% |
| EPS (Basic) | $0.03-25.0% | $0.00-100.0% | $0.02+100.0% | $0.00-100.0% | $0.04+100.0% | $0.03 | $0.01+116.7% | $0.01+111.1% |
| EPS (Diluted) | $0.02-50.0% | $0.00-100.0% | $0.020.0% | $0.00-100.0% | $0.04+100.0% | $0.03 | $0.02+133.3% | $0.01+111.1% |
| Diluted Shares (Avg) | 348M-2.5% | 341M-10.1% | N/A | 348M-10.5% | 357M-7.2% | 380M-2.7% | N/A | 389M-6.0% |
GDRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.3B+77.7% | $2.0B+56.0% | $1.4B+1.2% | $1.3B-2.2% | $1.3B-10.6% | $1.3B-10.9% | $1.4B-12.6% | $1.4B-20.7% |
| Current Assets | $1.6B+190.5% | $1.3B+134.4% | $643.1M-2.5% | $565.5M-9.8% | $550.6M-26.6% | $540.2M-26.3% | $659.3M-24.5% | $626.8M-35.3% |
| Cash & Equivalents | $296.1M+5.3% | $235.7M-21.7% | $261.8M-41.6% | $273.5M-35.5% | $281.3M-46.4% | $301.0M-43.6% | $448.3M-33.3% | $423.8M-46.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $182.1M-3.6% | $232.7M+45.3% | $235.7M+61.5% | $203.7M+55.8% | $189.0M+16.8% | $160.1M+10.6% | $145.9M+1.6% | $130.8M+8.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $430.3M+2.0% | $430.3M+2.0% | $430.3M+4.8% | $421.7M+2.7% | $421.7M+2.7% | $421.7M+2.7% | $410.8M0.0% | $410.8M-0.3% |
| Total Liabilities | $1.7B+150.9% | $1.4B+118.3% | $787.8M+18.7% | $724.8M+10.1% | $675.7M-16.2% | $640.9M-22.1% | $663.4M-19.8% | $658.4M-20.4% |
| Current Liabilities | $1.2B+784.5% | $859.2M+731.1% | $246.0M+98.5% | $181.9M+59.0% | $130.9M+27.7% | $103.4M-11.3% | $123.9M+1.1% | $114.4M-2.9% |
| Non-Current Liabilities | $537.5M-1.3% | $540.1M+0.5% | $541.8M+0.4% | $542.9M-0.2% | $544.8M-22.6% | $537.5M-23.9% | $539.5M-23.4% | $544.1M-23.3% |
| Long-Term Debt | $481.6M-0.7% | $482.4M-0.7% | $483.3M-0.7% | $484.1M-0.7% | $485.0M-24.9% | $485.8M-24.9% | $486.7M-24.9% | $487.6M-24.8% |
| Total Equity | $647.6M+0.7% | $622.0M-4.9% | $616.3M-15.0% | $600.7M-13.7% | $643.0M-3.9% | $654.3M+3.7% | $724.7M-4.9% | $696.4M-21.0% |
| Retained Earnings | -$1.4B+1.1% | -$1.4B+1.4% | -$1.4B+2.1% | -$1.4B+2.2% | -$1.4B+2.4% | -$1.4B+2.0% | -$1.4B+1.1% | -$1.4B-1.1% |
Not reported in any period shown, so not listed: Inventory.
GDRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $80.8M+63.0% | $11.8M+25.8% | $32.9M-26.5% | $76.0M-12.5% | $49.6M+411.1% | $9.4M-77.9% | $44.7M+182.0% | $86.9M+44.1% |
| Depreciation & Amortization | $22.3M+12.9% | $21.8M+4.2% | $23.1M+21.2% | $21.4M+22.2% | $19.7M+16.3% | $20.9M+31.2% | $19.1M-56.2% | $17.5M-46.9% |
| Stock-Based Compensation | N/A | $16.5M-13.9% | N/A | N/A | N/A | $19.2M-23.6% | N/A | N/A |
| Capital Expenditures | $362K-7.2% | $1.1M+700.0% | $1.2M+666.0% | $1.7M+333.7% | $390K+45.5% | $142K-65.1% | $162K-60.4% | $403K+107.7% |
| Free Cash Flow | $80.5M+63.6% | $10.7M+15.4% | $31.6M-29.0% | $74.3M-14.1% | $49.2M+421.5% | $9.3M-78.0% | $44.6M+188.4% | $86.5M+43.9% |
| Investing Cash Flow | -$14.4M+21.3% | -$21.6M+58.3% | -$31.8M-90.9% | -$18.0M-13.5% | -$18.3M-6.3% | -$51.9M-151.6% | -$16.6M-29.3% | -$15.9M-16.2% |
| Financing Cash Flow | -$6.0M+88.2% | -$16.3M+84.5% | -$12.8M-263.4% | -$65.8M+61.8% | -$50.9M-5794.4% | -$104.9M+34.8% | -$3.5M+97.2% | -$172.1M-1155.9% |
| Share Buybacks | $2.0M-95.8% | $12.6M-87.4% | $9.4M+4916.0% | $61.1M+1024.2% | $46.0M | $99.9M-34.8% | $188K-99.8% | $5.4M-29.6% |
Not reported in any period shown, so not listed: Dividends Paid.
GDRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.5%-3.9pp | 89.6%-3.8pp | 91.0%-2.8pp | 93.2%-0.9pp | 93.4%-0.6pp | 93.4%-0.3pp | 93.9%+1.6pp | 94.0%+4.4pp |
| Operating Margin | 11.8%-1.4pp | 7.2%-4.3pp | 11.7%+2.5pp | 7.5%-3.0pp | 13.2%+3.3pp | 11.5%+7.8pp | 9.2%+18.4pp | 10.4%+31.8pp |
| Net Margin | 4.3%-2.1pp | 0.6%-4.9pp | 2.8%-0.6pp | 0.6%-1.5pp | 6.3%+3.0pp | 5.5%+6.0pp | 3.4%+16.6pp | 2.0%+23.4pp |
| Return on Equity | 1.3%-0.7pp | 0.2%-1.5pp | 0.9%-0.1pp | 0.2%-0.4pp | 2.0%+1.0pp | 1.7%+1.8pp | 0.9%+4.3pp | 0.6%+4.9pp |
| Return on Assets | 0.4%-0.6pp | 0.1%-0.8pp | 0.4%-0.1pp | 0.1%-0.2pp | 1.0%+0.5pp | 0.9%+0.9pp | 0.5%+2.1pp | 0.3%+2.5pp |
| Current Ratio | 1.38-2.8x | 1.47-3.8x | 2.61-2.7x | 3.11-2.4x | 4.21-3.1x | 5.23-1.1x | 5.32-1.8x | 5.48-2.7x |
| Debt-to-Equity | 0.740.0x | 0.780.0x | 0.78+0.1x | 0.81+0.1x | 0.75-0.2x | 0.74-0.3x | 0.67-0.2x | 0.700.0x |
| Asset Turnover | 0.09-0.1x | 0.10-0.1x | 0.140.0x | 0.150.0x | 0.150.0x | 0.160.0x | 0.140.0x | 0.140.0x |
| FCF Margin | 40.2%+15.9pp | 5.5%+1.0pp | 16.3%-6.2pp | 37.9%-6.4pp | 24.2%+19.5pp | 4.6%-16.8pp | 22.4%+14.6pp | 44.3%+10.9pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| GoodRx Holdings, Inc. GDRX | FY2025 | $796.9M | $30.4M | 3.8% | $1.2B | 56/100 |
| Phreesia, Inc. PHR | FY2026 | $480.6M | $2.3M | 0.5% | $659.8M | 45/100 |
| Omnicell Inc OMCL | FY2025 | $1.2B | $2.1M | 0.2% | $1.6B | 42/100 |
| Teladoc Health, Inc. TDOC | FY2025 | $2.5B | -$200.3M | -7.9% | $1.1B | 41/100 |
| Schrodinger, Inc. SDGR | FY2025 | $255.9M | -$103.3M | -40.4% | $1.9B | 60/100 |
| 10x Genomics, Inc. TXG | FY2025 | $642.8M | -$43.5M | -6.8% | $9.5B | 72/100 |
Where GoodRx Holdings, Inc. Ranks
Frequently Asked Questions
What is GoodRx Holdings, Inc.'s annual revenue?
GoodRx Holdings, Inc. (GDRX) reported $796.9M in total revenue for fiscal year 2025. This represents a 0.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is GoodRx Holdings, Inc.'s revenue growing?
GoodRx Holdings, Inc. (GDRX) revenue grew by 0.6% year-over-year, from $792.3M to $796.9M in fiscal year 2025.
Is GoodRx Holdings, Inc. profitable?
Yes, GoodRx Holdings, Inc. (GDRX) reported a net income of $30.4M in fiscal year 2025, with a net profit margin of 3.8%.
What is GoodRx Holdings, Inc.'s EBITDA?
GoodRx Holdings, Inc. (GDRX) had EBITDA of $172.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does GoodRx Holdings, Inc. have?
As of fiscal year 2025, GoodRx Holdings, Inc. (GDRX) had $261.8M in cash and equivalents against $483.3M in long-term debt.
What is GoodRx Holdings, Inc.'s gross margin?
GoodRx Holdings, Inc. (GDRX) had a gross margin of 92.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is GoodRx Holdings, Inc.'s operating margin?
GoodRx Holdings, Inc. (GDRX) had an operating margin of 11.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is GoodRx Holdings, Inc.'s net profit margin?
GoodRx Holdings, Inc. (GDRX) had a net profit margin of 3.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is GoodRx Holdings, Inc.'s return on equity (ROE)?
GoodRx Holdings, Inc. (GDRX) has a return on equity of 4.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is GoodRx Holdings, Inc.'s free cash flow?
GoodRx Holdings, Inc. (GDRX) generated $164.4M in free cash flow during fiscal year 2025. This represents a -10.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is GoodRx Holdings, Inc.'s operating cash flow?
GoodRx Holdings, Inc. (GDRX) generated $167.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are GoodRx Holdings, Inc.'s total assets?
GoodRx Holdings, Inc. (GDRX) had $1.4B in total assets as of fiscal year 2025, including both current and long-term assets.
What are GoodRx Holdings, Inc.'s capital expenditures?
GoodRx Holdings, Inc. (GDRX) invested $3.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does GoodRx Holdings, Inc. spend on research and development?
GoodRx Holdings, Inc. (GDRX) invested $121.0M in research and development during fiscal year 2025.
What is GoodRx Holdings, Inc.'s current ratio?
GoodRx Holdings, Inc. (GDRX) had a current ratio of 2.61 as of fiscal year 2025, which is generally considered healthy.
What is GoodRx Holdings, Inc.'s debt-to-equity ratio?
GoodRx Holdings, Inc. (GDRX) had a debt-to-equity ratio of 0.78 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is GoodRx Holdings, Inc.'s return on assets (ROA)?
GoodRx Holdings, Inc. (GDRX) had a return on assets of 2.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is GoodRx Holdings, Inc.'s P/E ratio?
GoodRx Holdings, Inc. (GDRX) trades at 73.8x earnings, its market capitalization divided by net income of $16.2M net income, trailing 12 months to June 30, 2026. The market capitalization is $1.2B as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is GoodRx Holdings, Inc.'s price-to-sales ratio?
GoodRx Holdings, Inc. (GDRX) trades at 1.5x sales, its market capitalization divided by revenue of $785.2M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.2B as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is GoodRx Holdings, Inc.'s Altman Z-Score?
GoodRx Holdings, Inc. (GDRX) has an Altman Z-Score of 0.62, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is GoodRx Holdings, Inc.'s Piotroski F-Score?
GoodRx Holdings, Inc. (GDRX) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are GoodRx Holdings, Inc.'s earnings high quality?
GoodRx Holdings, Inc. (GDRX) has an earnings quality ratio of 5.52x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can GoodRx Holdings, Inc. cover its interest payments?
GoodRx Holdings, Inc. (GDRX) has an interest coverage ratio of 2.05x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is GoodRx Holdings, Inc.?
GoodRx Holdings, Inc. (GDRX) scores 56 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.